-
Mashup Score: 0
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0
A clinical trial sought to determine if flutamide is more effective with or without the addition of PROSTVAC in patients with nmCRPC.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
Could #flutamide be made more effective for patients with nmCRPC with the addition of PROSTVAC? Learn what researchers discovered about this treatment combination: https://t.co/nsInuvyQxL https://t.co/n3Jt8g0gZO
-
-
Mashup Score: 2
A substudy of the phase 3 CheckMate-901 trial met its primary end points of overall survival and progression-free survival at final analysis.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
A substudy of the phase 3 CheckMate-901 trial has met its primary end points of overall survival and progression-free survival at final analysis, demonstrating a potential benefit of #nivolumab plus #cisplatin-based chemotherapy for mUC. Learn more: https://t.co/SczFgRIUD7 https://t.co/swyQtbaOHN
-
-
Mashup Score: 2
Dr. Hutson details the recent CLEAR study data on the long-term survival after 4 years of follow-up for patients who received 1L lenvatinib plus pembrolizumab.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
At #ASCO23, IO/TKI vs IO/IO took center stage for metastatic #kidneycancer. Which is best for patients long-term? @DrTHut of @TexasOncology tells us where he stands... https://t.co/blayc66nv6 https://t.co/kr8wZwmGD9
-
-
Mashup Score: 1
Dr. Hutson provides an overview of different combination therapies used and being investigated in the first-line advanced renal cell carcinoma setting.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
.@DrTHut forecasts the future of #kidneycancer combination regimens. Will triplets or even quadruplets move treatment forward? @TexasOncology https://t.co/wbh6kd8SCY https://t.co/tvdmCKZIdc
-
-
Mashup Score: 0
Researchers utilized the ROBUUST database, a multi-institutional collaborative that includes 17 centers worldwide, to examine data from 687 patients with UTUC.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
Researchers utilized the ROBUUST database, a multi-institutional collaborative that includes 17 centers worldwide, to examine data from 687 patients with #UTUC to evaluate the impact of variant histology on patient outcomes. Learn more: https://t.co/nFoXh8KDOD https://t.co/OsIRKfDJLs
-
-
Mashup Score: 0
Several experts discuss the evolution of nephrectomy as a treatment approach, how it is used today, which patients are best suited for it, and more.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
We recently spoke with several experts in the field of #kidneycancer to discuss the evolution of #nephrectomy as a treatment approach, which patients are best suited for it, and how it figures to exist as a treatment option in coming years. Read more: https://t.co/Q1dIBHAX7x https://t.co/N7HGa6ZV8F
-
-
Mashup Score: 2
A group of researchers determined which types of tumors are unlikely to respond positively to BCG so that alternative treatments can be used for patients.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
A group of researchers set out to determine which types of tumors are unlikely to respond positively to BCG so that alternative treatments such as early cystectomy, targeted therapy, or immunotherapy can be administered to patients with NMIBC. Learn more: https://t.co/DFdlCvw93Y https://t.co/pemcf1MdPq
-
-
Mashup Score: 0
The IMmotion150, IMmotion151, and JAVELIN Renal 101 trials were assessed for OS, PFS, and overall response rates of anti-PD-L1 combinations.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
The IMmotion150, IMmotion151, and JAVELIN Renal 101 trials were assessed to determine the overall survival, progression-free survival, and overall response rates of anti-PD-L1 combinations. Learn more: https://t.co/l1EjlIVLpy https://t.co/HTTAzk474O
-
-
Mashup Score: 6
Drs. Matin and Ambinder contextualize the OLYMPUS trial as having practice-changing potential for patients with low-grade, low-volume UTUC.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
The OLYMPUS trial revealed practice-changing potential for patients with low-grade, low-volume #UTUC. Watch @SurenaMatinMD and @SimplyUroMD discuss the trial's findings: https://t.co/Qf2umyz3eZ https://t.co/X3e59d2nKT
-
.@WallisCJD spoke with Dr. Jonathan Coleman of @MSKCancerCenter on his phase 1 trial investigating VTP for #UTUC, as well as the ENLIGHTED trial on low-grade upper-tract cancers. What's the difference between photodynamic and VTP therapy? https://t.co/iq44YtCSIb https://t.co/gnCMHmHJEi